FIBROGEN INC (FGEN) Stock Fundamental Analysis
USA - NASDAQ:FGEN - US31572Q8814 - Common Stock
8.69 USD
-0.38 (-4.19%)
9.1 USD
+0.41 (+4.72%)
Taking everything into account, FGEN scores 2 out of 10 in our fundamental rating. FGEN was compared to 533 industry peers in the Biotechnology industry. FGEN may be in some trouble as it scores bad on both profitability and health. FGEN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year FGEN was profitable.
FGEN had a negative operating cash flow in the past year.
FGEN had negative earnings in each of the past 5 years.
FGEN had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
FGEN has a better Return On Assets (-1.16%) than 89.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.16% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-45.81%
ROA(5y)-39.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of FGEN (128.07%) is better than 99.25% of its industry peers.
In the last couple of years the Gross Margin of FGEN has declined.
FGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 128.07% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.51%
GM growth 5Y-13.76%
2. Health
2.1 Basic Checks
FGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
FGEN has more shares outstanding than it did 1 year ago.
FGEN has more shares outstanding than it did 5 years ago.
FGEN has a worse debt/assets ratio than last year.
2.2 Solvency
FGEN has an Altman-Z score of -16.62. This is a bad value and indicates that FGEN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of FGEN (-16.62) is worse than 82.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.62 |
ROIC/WACCN/A
WACC14.65%
2.3 Liquidity
A Current Ratio of 1.04 indicates that FGEN should not have too much problems paying its short term obligations.
The Current ratio of FGEN (1.04) is worse than 87.01% of its industry peers.
A Quick Ratio of 1.02 indicates that FGEN should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.02, FGEN is not doing good in the industry: 86.82% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 107.35% over the past year.
FGEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -36.71%.
Measured over the past years, FGEN shows a very negative growth in Revenue. The Revenue has been decreasing by -35.07% on average per year.
EPS 1Y (TTM)107.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.12%
Revenue 1Y (TTM)-36.71%
Revenue growth 3Y-49.88%
Revenue growth 5Y-35.07%
Sales Q2Q%-97.67%
3.2 Future
Based on estimates for the next years, FGEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.11% on average per year.
The Revenue is expected to grow by 9.58% on average over the next years. This is quite good.
EPS Next Y52.49%
EPS Next 2Y-13.35%
EPS Next 3Y-4.37%
EPS Next 5Y15.11%
Revenue Next Year-96.23%
Revenue Next 2Y-81.07%
Revenue Next 3Y-67.04%
Revenue Next 5Y9.58%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 3.85 indicates a rather cheap valuation of FGEN.
FGEN's Price/Earnings ratio is rather cheap when compared to the industry. FGEN is cheaper than 99.25% of the companies in the same industry.
When comparing the Price/Earnings ratio of FGEN to the average of the S&P500 Index (25.89), we can say FGEN is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for FGEN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.85 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
FGEN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
FGEN's earnings are expected to decrease with -4.37% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y-13.35%
EPS Next 3Y-4.37%
5. Dividend
5.1 Amount
No dividends for FGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
8.69
-0.38 (-4.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners26.49%
Inst Owner Change3.06%
Ins Owners1.41%
Ins Owner Change-0.02%
Market Cap35.11M
Revenue(TTM)29.62M
Net Income(TTM)-2.07M
Analysts80
Price Target43.86 (404.72%)
Short Float %2.63%
Short Ratio2.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)82.57%
Min EPS beat(2)20.04%
Max EPS beat(2)145.1%
EPS beat(4)4
Avg EPS beat(4)109.14%
Min EPS beat(4)20.04%
Max EPS beat(4)226.05%
EPS beat(8)7
Avg EPS beat(8)63%
EPS beat(12)8
Avg EPS beat(12)40.12%
EPS beat(16)11
Avg EPS beat(16)583.04%
Revenue beat(2)1
Avg Revenue beat(2)14.05%
Min Revenue beat(2)-49.76%
Max Revenue beat(2)77.86%
Revenue beat(4)3
Avg Revenue beat(4)39.29%
Min Revenue beat(4)-49.76%
Max Revenue beat(4)98.39%
Revenue beat(8)6
Avg Revenue beat(8)28.13%
Revenue beat(12)9
Avg Revenue beat(12)20.88%
Revenue beat(16)11
Avg Revenue beat(16)17.71%
PT rev (1m)0%
PT rev (3m)-82.8%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-54.63%
EPS NY rev (1m)0%
EPS NY rev (3m)53.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-43.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-32.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.85 | ||
| Fwd PE | N/A | ||
| P/S | 0.66 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)2.26
EY26.01%
EPS(NY)-15.42
Fwd EYN/A
FCF(TTM)-5.86
FCFYN/A
OCF(TTM)-5.8
OCFYN/A
SpS13.26
BVpS-55.2
TBVpS-55.2
PEG (NY)0.07
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.16% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 128.07% | ||
| FCFM | N/A |
ROA(3y)-45.81%
ROA(5y)-39.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.51%
GM growth 5Y-13.76%
F-Score3
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 15.38% | ||
| Cap/Sales | 0.47% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | -16.62 |
F-Score3
WACC14.65%
ROIC/WACCN/A
Cap/Depr(3y)133.57%
Cap/Depr(5y)124.53%
Cap/Sales(3y)11.27%
Cap/Sales(5y)9.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)107.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.12%
EPS Next Y52.49%
EPS Next 2Y-13.35%
EPS Next 3Y-4.37%
EPS Next 5Y15.11%
Revenue 1Y (TTM)-36.71%
Revenue growth 3Y-49.88%
Revenue growth 5Y-35.07%
Sales Q2Q%-97.67%
Revenue Next Year-96.23%
Revenue Next 2Y-81.07%
Revenue Next 3Y-67.04%
Revenue Next 5Y9.58%
EBIT growth 1Y21.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.35%
EBIT Next 3Y3.31%
EBIT Next 5Y0.07%
FCF growth 1Y92.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.59%
OCF growth 3YN/A
OCF growth 5YN/A
FIBROGEN INC / FGEN FAQ
What is the ChartMill fundamental rating of FIBROGEN INC (FGEN) stock?
ChartMill assigns a fundamental rating of 2 / 10 to FGEN.
Can you provide the valuation status for FIBROGEN INC?
ChartMill assigns a valuation rating of 4 / 10 to FIBROGEN INC (FGEN). This can be considered as Fairly Valued.
What is the profitability of FGEN stock?
FIBROGEN INC (FGEN) has a profitability rating of 2 / 10.
What is the financial health of FIBROGEN INC (FGEN) stock?
The financial health rating of FIBROGEN INC (FGEN) is 1 / 10.
What is the earnings growth outlook for FIBROGEN INC?
The Earnings per Share (EPS) of FIBROGEN INC (FGEN) is expected to grow by 52.49% in the next year.